Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
Webinar/Online
Thursday, November 6, 2025 at 7:00am ET - 8:00am ET
Add this event to your calendar
Info
Topic
Hear expert guidance on how to inform decisions about advancing therapy and to recognize all patients who would benefit from approved biologic therapies targeting IL-13 based on the pathophysiology of AD. In addition, gain knowledge on the clinical efficacy and safety of biologic therapies targeting IL-13 in moderate to severe AD.
Credits Offered
This event offers
1.0 CME credit
to attendees.
Accreditation Info:
1.00 AAPA Category 1 CME credit.
Additional Information
Who Should Attend
This education is intended for dermatologists, allergists, pediatricians, primary care providers, pharmacists, nurse practitioners, and physician associates who manage patients with moderate to severe atopic dermatitis.
Goal Statement
The goal of this educational activity is to improve learners’ knowledge, competence, and performance managing advanced therapy for patients with moderate to severe atopic dermatitis.
Target Audience
This education is intended for dermatologists, allergists, pediatricians, primary care providers, pharmacists, nurse practitioners, and physician associates who manage patients with moderate to severe atopic dermatitis.
Learning Objectives
Upon completion of this event, participants should be able to:
- Evaluate the therapeutic rationale for advanced therapies targeting IL-13 based on the pathophysiology of AD
- Assess the clinical profile, safety, and efficacy of advanced therapies targeting IL-13 in moderate to severe AD
- Recognize patient candidates for advanced biologic therapies targeting IL-13 in moderate to severe AD
Speakers
Assistant Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York